

FILE COPY
RECEIVED
SECRETARY OF THE SENATE
05 SEP 19 AM 11:00

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Fierce and Isakowitz</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>600 New Hampshire Ave NW #1000, Washington, DC 2</u>			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name <u>Mark Isakowitz</u>		Telephone <u>202/333-8667</u>	E-mail (optional) <u>misakowitz@erds.com</u>
5. Senate			
7. Client Name <input type="checkbox"/> Self <u>Generic Pharmaceutical Industry Association</u>		6. House	

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☒ OR Year End (July

9. Check if this filing amends a previously filed version of this report ☒

10. Check if this is a Termination Report ☐ ⇨ Termination Date _____

11. No Lot

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for the period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>100,000</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description. <input type="checkbox"/> Method A. Reporting amounts using LDA Code <input type="checkbox"/> Method B. Reporting amounts under section 1361 Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 1361 Internal Revenue Code

Signature _____

Printed Name and Title

Mark Isakowitz Partner



/

Name Fierce and Isakowitz Client Name Generic Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

H.R. 1598
S. 1172

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House + Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Don Fierce	
Mark Isakowitz	
Kate Braden	LA. Sen. Frist

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature _____ Date 8/16/99

Printed Name and Title Mark Isakowitz, Partner

